Solicitation of Comments on Dispensing of Controlled Substances for the Treatment of Pain, 2883 [05-906]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 11 / Tuesday, January 18, 2005 / Notices
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection:
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Certification on Agency Letterhead
Authorizing Purchase of Firearm for
Official Duties of Law Enforcement
Officer.
(3) Agency Form Number, if Any, and
the Applicable Component of the
Department of Justice Sponsoring the
Collection: Form Number: None. Bureau
of Alcohol, Tobacco, Firearms and
Explosives.
(4) Affected Public Who Will be Asked
or Required to Respond, as Well as a
Brief Abstract: Primary: State, Local or
Tribal Government. Other: None. The
letter is used by a law enforcement
officer to purchase handguns to be used
in his/her official duties from a licensed
firearm dealer anywhere in the country.
The letter shall state that the officer will
use the firearm in official duties and
that a records check reveals that the
purchasing officer has no convictions
for misdemeanor crimes of domestic
violence.
(5) An Estimate of the Total Number
of Respondents and the Amount of Time
Estimated for an Average Respondent to
Respond: It is estimated that 50,000
respondents will take 5 seconds to file
the letter.
(6) An Estimate of the Total Public
Burden (in Hours) Associated With the
Collection: There are an estimated 69
annual total burden hours associated
with this collection.
If additional information is required
contact: Brenda E. Dyer, Department
VerDate jul<14>2003
11:51 Jan 14, 2005
Jkt 205001
Clearance Officer, Policy and Planning
Staff, Justice Management Division,
Department of Justice, Patrick Henry
Building, Suite 1600, 601 D Street, NW.,
Washington, DC 20530.
Dated: January 12, 2005.
Brenda E. Dyer,
Department Clearance Officer, Department of
Justice.
[FR Doc. 05–901 Filed 1–14–05; 8:45 am]
BILLING CODE 4410–FY–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–261N]
Solicitation of Comments on
Dispensing of Controlled Substances
for the Treatment of Pain
Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Notice; solicitation of
comments.
AGENCY:
SUMMARY: On November 16, 2004, DEA
published in the Federal Register an
Interim Policy Statement on the
dispensing of controlled substances for
the treatment of pain. The Interim
Policy Statement stated that DEA would
address the subject in greater detail in
a future Federal Register document,
taking into consideration the views of
the medical community. DEA is hereby
seeking comments from physicians and
other interested members of the public
as to what areas of the law relating to
the dispensing of controlled substances
for the treatment of pain they would like
DEA to address in the upcoming
Federal Register document.
DATES: Written comments must be
postmarked, and electronic comments
must be sent, on or before March 21,
2005.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–261’’ on all written and
electronic correspondence. Written
comments being sent via regular mail
should be sent to the Deputy
Administrator, Drug Enforcement
Administration, Washington, DC 20537,
Attention: DEA Federal Register
Representative/CCD. Written comments
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/CCD,
2401 Jefferson-Davis Highway,
Alexandria, VA 22301.
Comments may be directly sent to
DEA electronically by sending an
electronic message to
dea.diversion.policy@usdoj.gov.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
2883
Comments may also be sent
electronically through https://
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
document is also available at the
https://www.regulations.gov Web site.
DEA will accept attachments to
electronic comments in Microsoft Word,
WordPerfect, Adobe PDF, or Excel file
formats only. DEA will not accept any
file format other than those specifically
listed here.
FOR FURTHER INFORMATION CONTACT:
Daniel Dormont, Senior Attorney, Drug
Enforcement Administration,
Washington, DC 20537; telephone: (202)
307–8010.
SUPPLEMENTARY INFORMATION:
On November 16, 2004, DEA
published in the Federal Register an
Interim Policy Statement on the
dispensing of controlled substances for
the treatment of pain. 69 FR 67170. The
Interim Policy Statement explained why
an earlier document, which appeared on
the DEA Office of Diversion Control
Web site in August 2004, contained
misstatements and was not approved as
an official statement of the agency. The
Interim Policy Statement corrected some
of the misstatements in the August 2004
document and announced that DEA
would address, in greater detail, the
subject of dispensing controlled
substances for the treatment of pain in
a future Federal Register document,
taking into consideration the views of
the medical community. This upcoming
document will stay within the scope of
DEA’s authority by addressing the law
the agency administers, the Controlled
Substances Act (CSA), and the DEA
regulations promulgated thereunder, as
well as the pertinent court decisions. As
indicated in the Interim Policy
Statement, the document will contain a
recitation of the relevant provisions of
the CSA and DEA regulations relating to
the dispensing of controlled substances
for the treatment of pain. The purpose
of this recitation will be to provide
guidance and reassurance to the
overwhelming majority of physicians
who engage in legitimate pain treatment
while deterring unlawful prescribing
and dispensing of pharmaceutical
controlled substances.
As was the case with the Interim
Policy Statement, none of the principles
addressed in the upcoming Federal
Register document will be new. Rather,
the document will reiterate legal
concepts that have been incorporated in
the federal laws and regulations for
many years and are reflected in federal
court decisions and DEA final
administrative orders. DEA recognizes
E:\FR\FM\18JAN1.SGM
18JAN1
]]>Agencies
[Federal Register Volume 70, Number 11 (Tuesday, January 18, 2005)]
[Notices]
[Page 2883]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-906]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-261N]
Solicitation of Comments on Dispensing of Controlled Substances
for the Treatment of Pain
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice; solicitation of comments.
-----------------------------------------------------------------------
SUMMARY: On November 16, 2004, DEA published in the Federal Register an
Interim Policy Statement on the dispensing of controlled substances for
the treatment of pain. The Interim Policy Statement stated that DEA
would address the subject in greater detail in a future Federal
Register document, taking into consideration the views of the medical
community. DEA is hereby seeking comments from physicians and other
interested members of the public as to what areas of the law relating
to the dispensing of controlled substances for the treatment of pain
they would like DEA to address in the upcoming Federal Register
document.
DATES: Written comments must be postmarked, and electronic comments
must be sent, on or before March 21, 2005.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-261'' on all written and electronic correspondence.
Written comments being sent via regular mail should be sent to the
Deputy Administrator, Drug Enforcement Administration, Washington, DC
20537, Attention: DEA Federal Register Representative/CCD. Written
comments sent via express mail should be sent to DEA Headquarters,
Attention: DEA Federal Register Representative/CCD, 2401 Jefferson-
Davis Highway, Alexandria, VA 22301.
Comments may be directly sent to DEA electronically by sending an
electronic message to dea.diversion.policy@usdoj.gov. Comments may also
be sent electronically through https://www.regulations.gov using the
electronic comment form provided on that site. An electronic copy of
this document is also available at the https://www.regulations.gov Web
site. DEA will accept attachments to electronic comments in Microsoft
Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not
accept any file format other than those specifically listed here.
FOR FURTHER INFORMATION CONTACT: Daniel Dormont, Senior Attorney, Drug
Enforcement Administration, Washington, DC 20537; telephone: (202) 307-
8010.
SUPPLEMENTARY INFORMATION:
On November 16, 2004, DEA published in the Federal Register an
Interim Policy Statement on the dispensing of controlled substances for
the treatment of pain. 69 FR 67170. The Interim Policy Statement
explained why an earlier document, which appeared on the DEA Office of
Diversion Control Web site in August 2004, contained misstatements and
was not approved as an official statement of the agency. The Interim
Policy Statement corrected some of the misstatements in the August 2004
document and announced that DEA would address, in greater detail, the
subject of dispensing controlled substances for the treatment of pain
in a future Federal Register document, taking into consideration the
views of the medical community. This upcoming document will stay within
the scope of DEA's authority by addressing the law the agency
administers, the Controlled Substances Act (CSA), and the DEA
regulations promulgated thereunder, as well as the pertinent court
decisions. As indicated in the Interim Policy Statement, the document
will contain a recitation of the relevant provisions of the CSA and DEA
regulations relating to the dispensing of controlled substances for the
treatment of pain. The purpose of this recitation will be to provide
guidance and reassurance to the overwhelming majority of physicians who
engage in legitimate pain treatment while deterring unlawful
prescribing and dispensing of pharmaceutical controlled substances.
As was the case with the Interim Policy Statement, none of the
principles addressed in the upcoming Federal Register document will be
new. Rather, the document will reiterate legal concepts that have been
incorporated in the federal laws and regulations for many years and are
reflected in federal court decisions and DEA final administrative
orders. DEA recognizes the desire of many physicians and members of the
public to have these concepts reiterated in a single, comprehensive
document. Toward that end, DEA is hereby seeking the input of
physicians, pharmacists, and other interested members of the public.
Any person who so desires should indicate, in writing, the areas of the
law relating to controlled substances that they would like DEA to
address in the upcoming document. DEA will consider all such comments
submitted on or before March 21, 2005.
Dated: January 11, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-906 Filed 1-14-05; 8:45 am]
BILLING CODE 4410-09-P
